EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹815 Cr
Expense Ratio
1.10%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+15.62%
+17.55% (Cat Avg.)
3 Years
+18.69%
+18.10% (Cat Avg.)
5 Years
+21.61%
+22.46% (Cat Avg.)
Since Inception
+22.51%
— (Cat Avg.)
Equity | ₹805.06 Cr | 98.79% |
Others | ₹9.89 Cr | 1.21% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹119.04 Cr | 14.61% |
Cipla Ltd | Equity | ₹68.81 Cr | 8.44% |
Torrent Pharmaceuticals Ltd | Equity | ₹57.45 Cr | 7.05% |
Apollo Hospitals Enterprise Ltd | Equity | ₹56.2 Cr | 6.90% |
Abbott India Ltd | Equity | ₹50.06 Cr | 6.14% |
Lupin Ltd | Equity | ₹39.79 Cr | 4.88% |
Aurobindo Pharma Ltd | Equity | ₹39.6 Cr | 4.86% |
Fortis Healthcare Ltd | Equity | ₹36.84 Cr | 4.52% |
Ajanta Pharma Ltd | Equity | ₹33.92 Cr | 4.16% |
Ipca Laboratories Ltd | Equity | ₹33.07 Cr | 4.06% |
Mankind Pharma Ltd | Equity | ₹24.39 Cr | 2.99% |
Alkem Laboratories Ltd | Equity | ₹24.3 Cr | 2.98% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹22.88 Cr | 2.81% |
Alembic Pharmaceuticals Ltd | Equity | ₹22.34 Cr | 2.74% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹21.6 Cr | 2.65% |
Jupiter Life Line Hospitals Ltd | Equity | ₹20.98 Cr | 2.57% |
Sai Life Sciences Ltd | Equity | ₹19.4 Cr | 2.38% |
Emcure Pharmaceuticals Ltd | Equity | ₹17.27 Cr | 2.12% |
Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹15.77 Cr | 1.93% |
Sanofi India Ltd | Equity | ₹13.17 Cr | 1.62% |
Vijaya Diagnostic Centre Ltd | Equity | ₹12.3 Cr | 1.51% |
Medi Assist Healthcare Services Ltd | Equity | ₹11.9 Cr | 1.46% |
Dr Reddy's Laboratories Ltd | Equity | ₹11.32 Cr | 1.39% |
Metropolis Healthcare Ltd | Equity | ₹10.51 Cr | 1.29% |
Procter & Gamble Health Ltd | Equity | ₹9.78 Cr | 1.20% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹8.17 Cr | 1.00% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹8.05 Cr | 0.99% |
Vinati Organics Ltd | Equity | ₹6.16 Cr | 0.76% |
Net Receivables / (Payables) | Cash | ₹-5.87 Cr | 0.72% |
Suraksha Diagnostic Ltd | Equity | ₹5.76 Cr | 0.71% |
Large Cap Stocks
31.49%
Mid Cap Stocks
44.15%
Small Cap Stocks
23.15%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹798.9 Cr | 98.03% |
Basic Materials | ₹6.16 Cr | 0.76% |
Standard Deviation
This fund
16.88%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.74
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since July 2019
Since November 2022
ISIN INF209KB1O25 | Expense Ratio 1.10% | Exit Load 1.00% | Fund Size ₹815 Cr | Age 5 years 9 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹3,67,306 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (17-Apr-25)
Returns (Since Inception)
Fund Size
₹815 Cr
Expense Ratio
1.10%
ISIN
INF209KB1O25
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
11 Jul 2019
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+15.62%
+17.55% (Cat Avg.)
3 Years
+18.69%
+18.10% (Cat Avg.)
5 Years
+21.61%
+22.46% (Cat Avg.)
Since Inception
+22.51%
— (Cat Avg.)
Equity | ₹805.06 Cr | 98.79% |
Others | ₹9.89 Cr | 1.21% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹119.04 Cr | 14.61% |
Cipla Ltd | Equity | ₹68.81 Cr | 8.44% |
Torrent Pharmaceuticals Ltd | Equity | ₹57.45 Cr | 7.05% |
Apollo Hospitals Enterprise Ltd | Equity | ₹56.2 Cr | 6.90% |
Abbott India Ltd | Equity | ₹50.06 Cr | 6.14% |
Lupin Ltd | Equity | ₹39.79 Cr | 4.88% |
Aurobindo Pharma Ltd | Equity | ₹39.6 Cr | 4.86% |
Fortis Healthcare Ltd | Equity | ₹36.84 Cr | 4.52% |
Ajanta Pharma Ltd | Equity | ₹33.92 Cr | 4.16% |
Ipca Laboratories Ltd | Equity | ₹33.07 Cr | 4.06% |
Mankind Pharma Ltd | Equity | ₹24.39 Cr | 2.99% |
Alkem Laboratories Ltd | Equity | ₹24.3 Cr | 2.98% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹22.88 Cr | 2.81% |
Alembic Pharmaceuticals Ltd | Equity | ₹22.34 Cr | 2.74% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹21.6 Cr | 2.65% |
Jupiter Life Line Hospitals Ltd | Equity | ₹20.98 Cr | 2.57% |
Sai Life Sciences Ltd | Equity | ₹19.4 Cr | 2.38% |
Emcure Pharmaceuticals Ltd | Equity | ₹17.27 Cr | 2.12% |
Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹15.77 Cr | 1.93% |
Sanofi India Ltd | Equity | ₹13.17 Cr | 1.62% |
Vijaya Diagnostic Centre Ltd | Equity | ₹12.3 Cr | 1.51% |
Medi Assist Healthcare Services Ltd | Equity | ₹11.9 Cr | 1.46% |
Dr Reddy's Laboratories Ltd | Equity | ₹11.32 Cr | 1.39% |
Metropolis Healthcare Ltd | Equity | ₹10.51 Cr | 1.29% |
Procter & Gamble Health Ltd | Equity | ₹9.78 Cr | 1.20% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹8.17 Cr | 1.00% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹8.05 Cr | 0.99% |
Vinati Organics Ltd | Equity | ₹6.16 Cr | 0.76% |
Net Receivables / (Payables) | Cash | ₹-5.87 Cr | 0.72% |
Suraksha Diagnostic Ltd | Equity | ₹5.76 Cr | 0.71% |
Large Cap Stocks
31.49%
Mid Cap Stocks
44.15%
Small Cap Stocks
23.15%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹798.9 Cr | 98.03% |
Basic Materials | ₹6.16 Cr | 0.76% |
Standard Deviation
This fund
16.88%
Cat. avg.
16.77%
Lower the better
Sharpe Ratio
This fund
0.74
Cat. avg.
0.75
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.30
Higher the better
Since July 2019
Since November 2022
ISIN INF209KB1O25 | Expense Ratio 1.10% | Exit Load 1.00% | Fund Size ₹815 Cr | Age 5 years 9 months | Lumpsum Minimum ₹1,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹307.40 Cr | - |
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹307.40 Cr | - |
PGIM India Healthcare Fund Direct Growth Very High Risk | 0.7% | 0.0% | ₹104.18 Cr | - |
PGIM India Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹104.18 Cr | - |
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹303.62 Cr | 26.8% |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk | 0.6% | 1.0% | ₹303.62 Cr | 29.0% |
DSP Nifty Healthcare ETF Regular Growth Very High Risk | 0.2% | - | ₹9.77 Cr | 15.8% |
Kotak Healthcare Fund Direct Growth Very High Risk | 0.8% | 0.0% | ₹411.54 Cr | 16.3% |
Kotak Healthcare Fund Regular Growth Very High Risk | 2.4% | 0.0% | ₹411.54 Cr | 14.4% |
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk | 2.1% | 1.0% | ₹1634.08 Cr | 27.7% |
Total AUM
₹3,67,306 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments